CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 155,095	$ 127,321	$ 443,954	$ 375,554	$ 509,338
Cost of revenues	35,372	32,092	103,715	95,724	128,280
Gross profit	119,723	95,229	340,239	279,830	381,058
Operating costs and expenses:
Research, development and clinical studies	51,882	53,623	158,435	168,754	223,062
Sales and marketing	59,830	57,964	171,652	167,621	226,809
General and administrative	40,103	41,887	117,344	124,609	164,057
Total operating costs and expenses	151,815	153,474	447,431	460,984	613,928
Operating income (loss)	(32,092)	(58,245)	(107,192)	(181,154)	(232,870)
Financial income (expenses), net	10,507	10,023	31,236	27,948	41,130
Income (loss) before income tax	(21,585)	(48,222)	(75,956)	(153,206)	(191,740)
Income tax	8,985	1,263	26,749	6,758	15,303
Net income (loss)	$ (30,570)	$ (49,485)	$ (102,705)	$ (159,964)	$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.28)	$ (0.46)	$ (0.95)	$ (1.51)	$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.28)	$ (0.46)	$ (0.95)	$ (1.51)	$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	108,247,716	106,772,814	107,679,501	106,219,194	106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	108,247,716	106,772,814	107,679,501	106,219,194	106,391,178